Defining cell-type specificity at the transcriptional level in human disease

Genome Research

Volumn 23, Issue 11, 2013, Pages 1862-1873

  Ju, Wenjun ^a,b   Greene, Casey S ^c,d,e   Eichinger, Felix ^a   Nair, Viji ^a   Hodgin, Jeffrey B ^a   Bitzer, Markus ^a   Lee, Young Suk ^c,d   Zhu, Qian ^c,d   Kehata, Masami ^f   Li, Min ^f   Jiang, Song ^a   Pia Rastaldi, Maria ^f   Cohen, Clemens D ^g   Troyanskaya, Olga G ^c,d   Kretzler, Matthias ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c PRINCETON UNIVERSITY   (United States)

^d Princeton University   (United States)

^e DARTMOUTH MEDICAL SCHOOL   (United States)

^f FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^g UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CELL LINEAGE; CELL SPECIFICITY; CHRONIC KIDNEY DISEASE; COMPUTER MODEL; CONTROLLED STUDY; FLUORESCENCE ANALYSIS; GENE EXPRESSION; GENETIC DISORDER; GENETIC TRANSCRIPTION; GLOMERULUS FILTRATION; HIGH THROUGHPUT SEQUENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; KIDNEY BIOPSY; MICRODISSECTION; PODOCYTE; PREDICTION; PRIORITY JOURNAL; TISSUE HOMOGENATE;

ANIMALS; ARTIFICIAL INTELLIGENCE; BIOPSY; CELL DIFFERENTIATION; CELL LINEAGE; COMPUTATIONAL BIOLOGY; COMPUTER SIMULATION; DATABASES, GENETIC; GENE EXPRESSION PROFILING; GENOME, HUMAN; HUMANS; KIDNEY DISEASES; MICE; NANOTECHNOLOGY; ORGAN SPECIFICITY; ORGANOGENESIS; PODOCYTES; RENAL INSUFFICIENCY, CHRONIC;

EID: 84884412556     PISSN: 10889051     EISSN: 15495469     Source Type: Journal    
DOI: 10.1101/gr.155697.113     Document Type: Article

References (59)

1. Beck LH, Bonegio RGB, Lambeau G, Beck DM, Powell DW, Cummins TD, Klein JB, Salant DJ. 2009. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 361: 11-21.
2. Bennett MR, Czech KA, Arend LJ, Witte DP, Devarajan P, Potter SS. 2007. Laser capture microdissection-microarray analysis of focal segmental glomerulosclerosis glomeruli. Nephron, Exp Nephrol 107: e30-e40.
3. Berthier CC, Bethunaickan R, Gonzalez-Rivera T, Nair V, Ramanujam M, Zhang W, Bottinger EP, Segerer S, Lindenmeyer M, Cohen CD, et al. 2012. Cross-species transcriptional network analysis defines shared inflammatory responses in murine and human lupus nephritis. J Immunol 189: 988-1001.
4. Bowman AW, Azzalini A. 2010. R package sm: nonparametric smoothing methods (version 2.2-4).
5. Brunskill EW, Georgas K, Rumballe B, Little MH, Potter SS. 2011. Defining the molecular character of the developing and adult kidney podocyte. PLoS ONE 6: e24640.
6. Cai JJ, Petrov DA. 2010. Relaxed purifying selection and possibly high rate of adaptation in primate lineage-specific genes. Genome Biol Evol 2: 393-409.
7. D'Agati VD. 2008. The spectrum of focal segmental glomerulosclerosis: New insights. Curr Opin Nephrol Hypertens 17: 271-281.
8. D'Agati VD, Kaskel FJ, Falk RJ. 2011. Focal segmental glomerulosclerosis. N Engl J Med 365: 2398-2411.
9. Doublier S, Salvidio G, Lupia E, Ruotsalainen V, Verzola D, Deferrari G, Camussi G. 2003. Nephrin expression is reduced in human diabetic nephropathy: Evidence for a distinct role for glycated albumin and angiotensin II. Diabetes 52: 1023-1030.
10. Edgar R, Domrachev M, Lash AE. 2002. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 30: 207-210.
11. Endlich N, Sunohara M, Nietfeld W, Wolski EW, Schiwek D, Kränzlin B, Gretz N, Kriz W, Eickhoff H, Endlich K. 2002. Analysis of differential gene expression in stretched podocytes: Osteopontin enhances adaptation of podocytes to mechanical stress. FAESB J 16: 1850-1852.
12. Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J, Richardson C, Kopp JB, Kabir MG, Backx PH, et al. 2008. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 358: 1129-1136.
13. Fukuda A, Wickman LT, Venkatareddy MP, Wang SQ, Chowdhury MA, Wiggins JE, Shedden KA, Wiggins RC. 2012. Urine podocin:nephrin mRNA ratio (PNR) as a podocyte stress biomarker. Nephrol Dial Transplant 27: 4079-4087.
14. Gadegbeku CA, Gipson DS, Holzman LB, Ojo AO, Song PXK, Barisoni L, Sampson MG, Kopp JB, Lemley KV, Nelson PJ, et al. 2013. Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach. Kidney Int 83: 749-756.
15. Genovese G, Friedman DJ, Ross MD, Lecordier L, Uzureau P, Freedman BI, Bowden DW, Langefeld CD, Oleksyk TK, Uscinski Knob AL, et al. 2010. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 329: 841-845.
16. Gerstein HC. 2001. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 286: 421-426.
17. Groop P-H, Thomas MC, Moran JL, Waden J, Thorn LM, Mäkinen V-P, Rosenga?rd-Bärlund M, Saraheimo M, Hietala K, Heikkilä O, et al. 2009. The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes. Diabetes 58: 1651-1658.
18. Halbritter J, Diaz K, Chaki M, Porath JD, Tarrier B, Fu C, Innis JL, Allen SJ, Lyons RH, Stefanidis CJ, et al. 2012. High-throughput mutation analysis in patients with a nephronophthisis-associated ciliopathy applying multiplexed barcoded array-based PCR amplification and nextgeneration sequencing. J Med Genet 49: 756-767.
19. Henger A, Kretzler M, Doran P, Bonrouhi M, Schmid H, Kiss E, Cohen CD, Madden S, Porubsky S, Gröne EF, et al. 2004. Gene expression fingerprints in human tubulointerstitial inflammation and fibrosis as prognostic markers of disease progression. Kidney Int 65: 904-917.
20. Higgins JPT, Wang L, Kambham N, Montgomery K, Mason V, Vogelmann SU, Lemley KV, Brown PO, Brooks JD, van de Rijn M. 2004. Gene expression in the normal adult human kidney assessed by complementary DNA microarray. Mol Biol Cell 15: 649-656.
21. Hinkes B, Wiggins RC, Gbadegesin R, Vlangos CN, Seelow D, Nürnberg G, Garg P, Verma R, Chaib H, Hoskins BE, et al. 2006. Positional cloning uncovers mutations in PLCE1 responsible for a nephrotic syndrome variant that may be reversible. Nat Genet 38: 1397-1405.
22. Hodgin JB, Borczuk AC, Nasr SH, Markowitz GS, Nair V, Martini S, Eichinger F, Vining C, Berthier CC, Kretzler M, et al. 2010. A molecular profile of focal segmental glomerulosclerosis from formalin-fixed, paraffinembedded tissue. Am J Pathol 177: 1674-1686.
23. Huttenhower C, Schroeder M, Chikina MD, Troyanskaya OG. 2008. The Sleipnir library for computational functional genomics. Bioinformatics 24: 1559-1561.
24. Ingelfinger JR. 2011. MYO1E, focal segmental glomerulosclerosis, and the cytoskeleton. N Engl J Med 365: 368-369.
25. Jain S, De Petris L, Hoshi M, Akilesh S, Chatterjee R, Liapis H. 2011. Expression profiles of podocytes exposed to high glucose reveal new insights into early diabetic glomerulopathy. Lab Invest 91: 488-498.
26. Joachims T. 2006. Training linear SVMs in linear time. In Proceedings of the 12th ACM SIGKDD International Conference on Knowledge Discovery and Data Mining-KDD '06, p. 217. ACM Press, New York, NY.
27. Ju W, Eichinger F, Bitzer M, Oh J, McWeeney S, Berthier CC, Shedden K, Cohen CD, Henger A, Krick S, et al. 2009. Renal gene and protein expression signatures for prediction of kidney disease progression. Am J Pathol 174: 2073-2085.
28. Kao WHL, Klag MJ, Meoni LA, Reich D, Berthier-Schaad Y, Li M, Coresh J, Patterson N, Tandon A, Powe NR, et al. 2008. MYH9 is associated with nondiabetic end-stage renal disease in African Americans. Nat Genet 40: 1185-1192.
29. Keshava Prasad TS, Goel R, Kandasamy K, Keerthikumar S, Kumar S, Mathivanan S, Telikicherla D, Raju R, Shafreen B, Venugopal A, et al. 2009. Human Protein Reference Database: 2009 update. Nucleic Acids Res 37: D767-D772.
30. Kim JM,Wu H, Green G,Winkler CA, Kopp JB, Miner JH, Unanue ER, Shaw AS. 2003. CD2-associated protein haploinsufficiency is linked to glomerular disease susceptibility. Science 300: 1298-1300.
31. Koop K, Eikmans M, Baelde HJ, Kawachi H, De Heer E, Paul LC, Bruijn JA. 2003. Expression of podocyte-associated molecules in acquired human kidney diseases. J Am Soc Nephrol 14: 2063-2071.
32. Kopp JB, Smith MW, Nelson GW, Johnson RC, Freedman BI, Bowden DW, Oleksyk T, McKenzie LM, Kajiyama H, Ahuja TS, et al. 2008. MYH9 is amajor-effect risk gene for focal segmental glomerulosclerosis. Nat Genet 40: 1175-1184.
33. Kopp JB, Nelson GW, Sampath K, Johnson RC, Genovese G, An P, Friedman D, Briggs W, Dart R, Korbet S, et al. 2011. APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol 22: 2129-2137.
34. Köttgen A, Pattaro C, Böger CA, Fuchsberger C, OldenM, Glazer NL, Parsa A, Gao X, Yang Q, Smith AV, et al. 2010. New loci associated with kidney function and chronic kidney disease. Nat Genet 42: 376-384.
35. Kriz W, Elger M, Nagata M, Kretzler M, Uiker S, Koeppen-Hageman I, Tenschert S, Lemley KV. 1994. The role of podocytes in the development of glomerular sclerosis. Kidney Int Suppl 45: S64-S72.
36. Kuhn A, Thu D,Waldvogel HJ, Faull RLM, Luthi-Carter R. 2011. Populationspecific expression analysis (PSEA) reveals molecular changes in diseased brain. Nat Methods 8: 945-947.
37. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, Kusek JW, Van Lente F. 2006. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 145: 247-254.
38. LindenmeyerMT, Eichinger F, Sen K, Anders H-J, Edenhofer I, Mattinzoli D, Kretzler M, RastaldiMP, Cohen CD. 2010. Systematic analysis of a novel human renal glomerulus-enriched gene expression dataset. PLoS ONE 5: e11545.
39. Lorz C, Benito-Mart?n A, Boucherot A, Ucero AC, Rastaldi MP, Henger A, Armelloni S, Santamar?a B, Berthier CC, Kretzler M, et al. 2008. The death ligand TRAIL in diabetic nephropathy. J Am Soc Nephrol 19: 904-914.
40. Maglott D,Ostell J, Pruitt KD, Tatusova T. 2011. Entrez Gene: Gene-centered information at NCBI. Nucleic Acids Res 39: D52-D57.
41. McMahon AP, Aronow BJ, Davidson DR, Davies JA, GaidoKW, Grimmond S, Lessard JL, Little MH, Potter SS, Wilder EL, et al. 2008. GUDMAP: The genitourinary developmental molecular anatomy project. J Am Soc Nephrol 19: 667-671.
42. Mele C, Iatropoulos P, Donadelli R, Calabria A, Maranta R, Cassis P, Buelli S, Tomasoni S, Piras R, Krendel M, et al. 2011. MYO1E mutations and childhood familial focal segmental glomerulosclerosis.N Engl J Med 365: 295-306.
43. Niewold TB. 2011. Stabilizing the kidney's skeleton. Sci Translational Med 3: 95ec128.
44. Pavenstädt H. 2000. Roles of the podocyte in glomerular function. Am J Physiol Renal Physiol 278: F173-F179.
45. Reddy MM, Wilson R, Wilson J, Connell S, Gocke A, Hynan L, German D, Kodadek T. 2011. Identification of candidate IgG biomarkers for Alzheimer's disease via combinatorial library screening. Cell 144: 132-142.
46. Reich HN, Tritchler D, Cattran DC, Herzenberg AM, Eichinger F, Boucherot A, Henger A, Berthier CC, Nair V, Cohen CD, et al. 2010. A molecular signature of proteinuria in glomerulonephritis. PLoS ONE 5: e13451.
47. Roselli S, Heidet L, Sich M, Henger A, Kretzler M, Gubler M-C, Antignac C. 2004. Early glomerular filtration defect and severe renal disease in podocin-deficient mice. Mol Cell Biol 24: 550-560.
48. Saleem MA, Zavadil J, Bailly M, McGee K, Witherden IR, Pavenstadt H, Hsu H, Sanday J, Satchell SC, Lennon R, et al. 2008. The molecular and functional phenotype of glomerular podocytes reveals key features of contractile smooth muscle cells. Am J Physiol Renal Physiol 295: F959-F970.
49. Sato Y, Wharram BL, Lee SK, Wickman L, Goyal M, Venkatareddy M, Chang JW, Wiggins JE, Lienczewski C, Kretzler M, et al. 2009. Urine podocyte mRNAs mark progression of renal disease. J Am Soc Nephrol 20: 1041-1052.
50. Sawai K, Mukoyama M, Mori K, Yokoi H, KoshikawaM, Yoshioka T, Takeda R, Sugawara A, Kuwahara T, Saleem MA, et al. 2006. Redistribution of connexin43 expression in glomerular podocytes predicts poor renal prognosis in patients with type 2 diabetes and overt nephropathy. Nephrol Dial Transplant 21: 2472-2477.
51. Schmid H, Boucherot A, Yasuda Y, Henger A, Brunner B, Eichinger F, Nitsche A, Kiss E, Bleich M, Gröne H-J, et al. 2006.Modular activation of nuclear factor-kB transcriptional programs in human diabetic nephropathy. Diabetes 55: 2993-3003.
52. Shen-Orr SS, Tibshirani R, Khatri P, Bodian DL, Staedtler F, Perry NM, Hastie T, Sarwal MM, Davis MM, Butte AJ. 2010. Cell type-specific gene expression differences in complex tissues. Nat Methods 7: 287-289.
53. Sistani L, Dunér F, Udumala S, Hultenby K, Uhlen M, Betsholtz C, Tryggvason K, Wernerson A, Patrakka J. 2011. Pdlim2 is a novel actin-regulating protein of podocyte foot processes. Kidney Int 80: 1045-1054.
54. Steiglitz BM, Keene DR, Greenspan DS. 2002. PCOLCE2 encodes a functional procollagen C-proteinase enhancer (PCPE2) that is a collagen-binding protein differing in distribution of expression and post-translational modification from the previously described PCPE1. J Biol Chem 277: 49820-49830.
55. TanakaM, Asada M, Higashi AY, Nakamura J, Oguchi A, Tomita M, Yamada S, Asada N, Takase M, Okuda T, et al. 2010. Loss of the BMP antagonist USAG-1 ameliorates disease in a mouse model of the progressive hereditary kidney disease Alport syndrome. J Clin Invest 120: 768-777.
56. Tusher VG, Tibshirani R, Chu G. 2001. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci 98: 5116-5121.
57. Winter EE, Goodstadt L, Ponting CP. 2004. Elevated rates of protein secretion, evolution, and disease among tissue-specific genes. Genome Res 14: 54-61.
58. Woroniecka KI, Park ASD, Mohtat D, Thomas DB, Pullman JM, Susztak K. 2011. Transcriptome analysis of human diabetic kidney disease. Diabetes 60: 2354-2369.
59. Yaoita E, Yao J, Yoshida Y, Morioka T, Nameta M, Takata T, Kamiie J, Fujinaka H, Oite T, Yamamoto T. 2002. Up-regulation of connexin43 in glomerular podocytes in response to injury. Am J Pathol 161: 1597-1606.